Tesofensine for weight loss: promising pipeline drug or premature hype?

What did @dr_jonesdc actually say?

The creator, identifying as a DC (doctor of chiropractic), pitched tesofensine as an option for people who don't qualify for GLP-1 medications due to contraindications like pancreatitis, thyroid cancer history, or conflicting diabetes drugs. He described it as a "triple monoamine reuptake inhibitor" that raises dopamine, serotonin, and norepinephrine, claiming this combination reduces cravings, addresses physical hunger, and boosts resting metabolism. He also implied his clinic is already using it with patients seeing "high levels of success."

Worth noting: he consistently called it "tesofencing" throughout, which is either a slip or an autocorrect casualty. The drug is tesofensine. Small thing, but it signals a casual familiarity with a compound he's presenting as a serious clinical alternative.

He also referenced a Facebook post going viral as evidence the information is valuable. Virality is not a clinical argument. That framing should raise a flag immediately.

Does the science back this up?

Partially, yes, but with significant asterisks. Tesofensine does exist, it does inhibit reuptake of dopamine, serotonin, and norepinephrine, and early trial data showed genuinely impressive weight loss numbers. The phase 2 trial by Astrup et al. (2008, The Lancet) found weight loss of 6.5 to 12.8 kg over 24 weeks depending on dose, which outperformed most comparators at the time.

However, tesofensine is not approved by the FDA. It is not approved in the EU. It has never completed phase 3 trials. The cardiovascular side effect profile, including elevated heart rate and blood pressure, caused enough concern to stall development. A study by Lehr et al. (2012, Obesity) noted dose-dependent increases in heart rate averaging 7-8 bpm at the higher doses, which is not trivial in a weight loss population that already carries cardiovascular risk.

The norepinephrine-raises-metabolism claim has some mechanistic support but is far more nuanced than "you will literally burn more calories at rest." Sympathomimetic effects do increase thermogenesis modestly, but the magnitude in humans is inconsistent across studies and does not translate to the dramatic metabolic shift implied here.

What did they get wrong (or right)?

Credit where it's due: the basic neuroscience isn't embarrassing. Dopamine's role in reward-driven eating behavior is well-documented. Serotonin's involvement in satiety signaling, particularly via 5-HT2C receptors in the hypothalamus, is legitimate science. The triple reuptake inhibitor mechanism is accurately described at a surface level.

What he got wrong, or at minimum dramatically oversimplified, is the safety and regulatory status. Presenting an unapproved compound to nearly 10,000 viewers as a ready clinical alternative to GLP-1s, without once mentioning it has no FDA approval, no completed phase 3 data, and a documented cardiovascular risk signal, is a serious omission. That's not a technicality. That's the part patients need to know first.

He also conflated the mechanism of GLP-1 medications with tesofensine's mechanism in a way that implies equivalent efficacy. GLP-1 agonists affect gut motility, gastric emptying, and pancreatic function in addition to central appetite regulation. Tesofensine works almost entirely centrally. These are not interchangeable profiles.

His claim that serotonin "plays more of an effect on the physical hunger" versus dopamine's emotional hunger is an oversimplification that doesn't hold up well under scrutiny. Both systems are deeply integrated in feeding behavior, and drawing clean lines between them is not supported by current neuroscience literature.

What should you actually know?

Tesofensine is a real compound with real early-stage data, but it is not an approved medication anywhere in the world as of 2024. If a clinic is offering it, they are likely dispensing it as a compounded preparation, which operates under different regulatory standards than approved drugs. Compounded tesofensine is not the same as a tested, approved pharmaceutical product, and anyone presenting it that way is not being straight with you.

The Astrup 2008 Lancet data is the most-cited evidence base, and while the weight loss figures were notable, that trial was industry-funded, relatively short, and never followed up with the phase 3 data needed for approval. The cardiovascular signal was enough to halt that pathway.

If you've been told you don't qualify for GLP-1 therapy, the next conversation should be with a licensed prescriber reviewing your full medical history, not a TikTok video recommending an unapproved compound. There are FDA-approved alternatives worth discussing: naltrexone-bupropion (Contrave), phentermine-topiramate (Qsymia), and orlistat all have approval and long-term safety data. Those aren't as exciting to post about, but they exist for a reason.